Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.
The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.
The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.
Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).
All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.
Keywords: MASCC–ESMO Clinical Practice Guideline; chemotherapy; nausea and vomiting; prevention; radiotherapy.